Dehydration on GLP-1: When to See a Doctor

What the GLP-1 labels actually flag

Dehydration turns up in GLP-1 labeling as a kidney problem. The Wegovy label lists acute kidney injury due to volume depletion under warnings and tells prescribers to monitor renal function in patients who report reactions that could lead to volume depletion [1].

The Foundayo label is more explicit: reports of acute kidney injury, in some cases requiring hemodialysis, have occurred in patients treated with GLP-1 receptor agonists or with Foundayo, and the majority of reported events were in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [2]. It asks for renal function monitoring in patients reporting those reactions, especially during dosage initiation and escalation [2].

The pattern in both labels is the same: gastrointestinal symptoms can cause dehydration, and dehydration can be followed by acute kidney injury [1][2].

How common the GI reactions are

Both labels state that the drug delays gastric emptying, and both say the drug is not recommended in people with severe gastroparesis [1][2].

In the Wegovy weight-management trials, 2,116 adults took 2.4 mg. Nausea occurred in 44%, diarrhea in 30%, vomiting in 24% and constipation in 24%, against 16%, 16%, 6% and 11% with placebo. Permanent discontinuation for adverse reactions was 6.8% on Wegovy versus 3.2% on placebo [1].

With tirzepatide at 15 mg, pooled across weight-management trials, nausea occurred in 28%, vomiting in 13%, diarrhea in 23% and constipation in 11%, against 8%, 2%, 8% and 5% on placebo [4]. Tirzepatide is a GIP and GLP-1 receptor agonist and is commonly grouped with the GLP-1 drugs [4].

With orforglipron (Foundayo) 17.2 mg, nausea occurred in 35%, constipation in 24%, diarrhea in 25% and vomiting in 24%, against 10%, 9%, 11% and 4% on placebo. Severe gastrointestinal reactions were reported in about 3% of orforglipron-treated patients versus 1% on placebo [2].

The labels themselves say rates from different trials cannot be directly compared [1][2], so these numbers should not be ranked across drugs.

Timing: dose escalation

The Foundayo label says nausea, vomiting and diarrhea were more frequent during dose escalation and decreased over time [2]. Products in this class start at a low dose and step up over weeks to reduce GI side effects [1][2].

One symptom in this picture is not a dehydration story at all. Both labels describe persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting, as possible signs of acute pancreatitis, and both direct discontinuation of the drug if pancreatitis is suspected [1][2].

Dizziness and low blood pressure

Dizziness is a listed common adverse reaction to Wegovy, reported by 8% of patients on 2.4 mg versus 4% on placebo, and the same label reports mean resting heart rate increases of 1 to 4 beats per minute [1]. In the Foundayo weight-management trials, hypotension occurred in 2% of treated patients versus 0.5% on placebo, and in 4% versus 1% among patients who were also taking antihypertensive medicines [2]. The available trial data do not identify the cause of an individual's light-headedness [1][2].

What to drink

WHO and UNICEF recommend oral rehydration salts solution, a glucose-electrolyte mix that can prevent dehydration from diarrhea when extra fluids are given at home and can treat it in all but the most severe cases [3].